Efficacy of adalimumab in Behçet's disease. Description of 6 cases

Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of who...

Full description

Saved in:
Bibliographic Details
Published in:Reumatología clinica (Barcelona) 2011, Vol.7 (4), p.258-261
Main Authors: Calvo Catalá, Javier, Campos Fernandez, Cristina, Rueda Cid, Amalia, Gonzalez-Cruz Cervellera, Maria Isabel, Baixauli Rubio, Aurelio, Pastor Cubillo, Maria Dolores
Format: Article
Language:English
Subjects:
Adalimumab
Anti-TNF
Behçet's disease
Enfermedad de Behçet
Uveitis
Uveítis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab. La enfermedad de Behçet (EB) es una vasculitis sistémica, y afecta con mayor agresividad a varones jóvenes. Sus manifestaciones más frecuentes son las aftas orogenitales, la uveítis y las lesiones cutáneas. Analizamos 6 pacientes con EB, que recibieron adalimumab para controlar la enfermedad. Todos habían recibido terapia inmunosupresora, además 2 de ellos recibieron infliximab. Observamos una buena respuesta clínica al fármaco. Actualmente, con un seguimiento medio de 26,8 meses, los pacientes siguen en tratamiento con adalimumab, con buen control clínico y sin que se hayan detectado efectos adversos relacionados con el anti-TNF.
ISSN:2173-5743
2173-5743
DOI:10.1016/S2173-5743(11)70056-9